Correlations Between Gut Microbiome Changes, Gut Barrier Function, and Immune Homeostasis in COVID-19 Patients: The Role of Gut Microbiota in Immunity and Cancer Prevention
DOI:
https://doi.org/10.56294/hl2025354Keywords:
Acute Invasive Fungal Rhino-Sinusitis (AIFRS), Inpatients, Epidemiology, Pathogen Diversity, Coexisting InfectionsAbstract
Systemic inflammation and immunological dysregulation are linked to COVID-19 infection, and there is mounting evidence that gut barrier failure and gut microbiota dysbiosis are related. Gaining knowledge of these relationships could help explain how diseases develop. By measuring biomarkers and cytokine levels, this research aims to analyze the relationships among gut microbiota alterations, gut barrier function, and immunological homeostasis in COVID-19 patients. Using IBM SPSS (version 26) with Pearson Correlation, Chi-Square testing, independent t-tests, and Multivariate Regression analysis, a comparative study was conducted using gut barrier biomarkers (Zonulin, LPS, I-FABP) and cytokine levels (IL-6, IL-10, TNF-α). In COVID-19 individuals, there were notable variations in gut barrier biomarkers and cytokine levels, with robust associations suggesting a connection between immune dysregulation and gut barrier failure. Gut microbiota dysbiosis and gut barrier dysfunction are significantly associated with immune homeostasis disturbance in COVID-19 patients, which may be a contributing factor to the disease's severity and progression.
References
1. Gusev E, Sarapultsev A, Solomatina L, Chereshnev V. SARS-CoV-2-specific immune response and the pathogenesis of COVID-19. International journal of molecular sciences. 2022 Feb 2;23(3):1716.https://doi.org/10.3390/ijms23031716
2. Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr 1;70(4):698-706.https://doi.org/10.1136/gutjnl-2020-323020
3. Zuo T, Liu Q, Zhang F, Lui GC, Tso EY, Yeoh YK, Chen Z, Boon SS, Chan FK, Chan PK, Ng SC. Depicting SARS-CoV-2 fecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021 Feb 1;70(2):276-84.https://doi.org/10.1136/gutjnl-2020-322294
4. Vodnar DC, Mitrea L, Teleky BE, Szabo K, Călinoiu LF, Nemeş SA, Martău GA. Coronavirus disease (COVID-19) caused by (SARS-CoV-2) infections: a real challenge for human gut microbiota. Frontiers in cellular and infection microbiology. 2020 Dec 9;10:575559.https://doi.org/10.3389/fcimb.2020.575559
5. Ioannidis JP. Global perspective of COVID‐19 epidemiology for a full‐cycle pandemic. European journal of clinical investigation. 2020 Dec;50(12):e13423.https://doi.org/10.1111/eci.13423
6. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D, Xu Y. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care. 2020 Dec;24:1-0.https://doi.org/10.1186/s13054-020-03120-0
7. Mahmud I, Garrett TJ. Mass spectrometry techniques in emerging pathogens studies: COVID-19 perspectives. Journal of the American Society for Mass Spectrometry. 2020 Sep 3;31(10):2013-24.https://doi.org/10.1021/jasms.0c00238
8. Luo W, Zhang JW, Zhang W, Lin YL, Wang Q. Circulating levels of IL‐2, IL‐4, TNF‐α, IFN‐γ, and C‐reactive protein are not associated with severity of COVID‐19 symptoms. Journal of medical virology. 2020 Jun 19;93(1):89.https://doi.org/10.1002/jmv.26156
9. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity. 2020 May 1;109:102433.https://doi.org/10.1016/j.jaut.2020.102433
10. Assimakopoulos SF, Eleftheriotis G, Lagadinou M, Karamouzos V, Dousdampanis P, Siakallis G, Marangos M. SARS CoV-2-induced viral sepsis: the role of gut barrier dysfunction. Microorganisms. 2022 May 19;10(5):1050.https://doi.org/10.3390/microorganisms10051050
11. Tsounis EP, Triantos C, Konstantakis C, Marangos M, Assimakopoulos SF. Intestinal barrier dysfunction is a key driver of severe COVID-19. World Journal of Virology. 2023 Mar 25;12(2):68.https://doi.org/10.5501/wjv.v12.i2.68
12. Sharma L, Riva A. Intestinal barrier function in health and disease—any role of SARS-CoV-2?. Microorganisms. 2020 Nov 6;8(11):1744. https://doi.org/10.3390/microorganisms8111744
13. Rastogi S, Mohanty S, Sharma S, Tripathi P. Possible role of gut microbes and host's immune response in the gut–lung homeostasis. Frontiers in immunology. 2022 Oct 4;13:954339.https://doi.org/10.3389/fimmu.2022.954339
14. Dhar D, Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus research. 2020 Aug 1;285:198018.https://doi.org/10.1016/j.virusres.2020.198018
15. Di Stadio A, Costantini C, Renga G, Pariano M, Ricci G, Romani L. The microbiota/host immune system interaction in the nose to protect from COVID-19. Life. 2020 Dec 11;10(12):345.https://doi.org/10.3390/life10120345
16. Shen S, Gong M, Wang G, Dua K, Xu J, Xu X, Liu G. COVID-19 and gut injury. Nutrients. 2022 Oct 20;14(20):4409.https://doi.org/10.3390/nu14204409
17. Marrella V, Nicchiotti F, Cassani B. Microbiota and immunity during respiratory infections: lung and gut affair. International journal of molecular sciences. 2024 Apr 5;25(7):4051.https://doi.org/10.3390/ijms25074051
18. Donzelli S, Ciuffreda L, Pontone M, Betti M, Massacci A, Mottini C, De Nicola F, Orlandi G, Goeman F, Giuliani E, Sperandio E. Optimizing the Illumina COVIDSeq laboratory and bioinformatics pipeline on thousands of samples for SARS-CoV-2 Variants of Concern tracking. Computational and structural biotechnology journal. 2022 Jan 1;20:2558-63.https://doi.org/10.1016/j.csbj.2022.05.033
19. Zhang S, Zhu Q, Zhan C, Cheng W, Mingfang X, Fang M, Fang L. Acupressure therapy and Liu Zi Jue Qigong for pulmonary function and quality of life in patients with severe novel coronavirus pneumonia (COVID-19): a study protocol for a randomized controlled trial. Trials. 2020 Dec;21:1-1.https://doi.org/10.1016/S2213-2600(20)30079-5.
20. Muhamad Rifki Ramadhan R. Comparison of Metagenomic Tools in Gut Microbiome Analysis of COVID-19 Patients.https://studenttheses.uu.nl/handle/20.500.12932/42280
21. Nguyen LH, Okin D, Drew DA, Battista VM, Jesudasen SJ, Kuntz TM, Bhosle A, Thompson KN, Reinicke T, Lo CH, Woo JE. Metagenomic assessment of gut microbial communities and risk of severe COVID-19. Genome Medicine. 2023 Jul 12;15(1):49.https://doi.org/10.1186/s13073-023-01202-6
22. Zhou T, Zeng Y, Wu J, Li J, Yan J, Meng W, Han H, Feng F, He J, Zhao S, Zhou P. SARS-CoV-2 triggered excessive inflammation and abnormal energy metabolism in gut microbiota. bioRxiv. 2021 Nov 9:2021-11.https://doi.org/10.1101/2021.11.08.467715
23. Catinean A, Sida A, Silvestru C, Balan GG. Ongoing treatment with a spore-based probiotic containing five strains of bacillus improves outcomes of mild COVID-19. Nutrients. 2023 Jan 17;15(3):488.https://doi.org/10.3390/nu15030488
24. Mańkowska-Wierzbicka D, Zuraszek J, Wierzbicka A, Gabryel M, Mahadea D, Baturo A, Zakerska-Banaszak O, Slomski R, Skrzypczak-Zielinska M, Dobrowolska A. Alterations in gut microbiota composition in patients with COVID-19: a pilot study of whole hypervariable 16S rRNA gene sequencing. Biomedicines. 2023 Jan 27;11(2):367.https://doi.org/10.3390/biomedicines11020367.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Geetika M. Patel, Avni Garg , Abhijeet Nashte , Himanshu Makhija , Kasturi Rohini (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
